In a 2023 study, a potential therapeutic target, Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), was identified through AAA's genome-wide association meta-analysis of 121 independent risk loci. This evidence concerns the gene PCSK9 and triple-A syndrome.